chr8-19951924-G-A
Position:
Variant summary
Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1
The NM_000237.3(LPL):c.405G>A(p.Val135Val) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0342 in 1,614,046 control chromosomes in the GnomAD database, including 1,345 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.055 ( 347 hom., cov: 32)
Exomes 𝑓: 0.032 ( 998 hom. )
Consequence
LPL
NM_000237.3 synonymous
NM_000237.3 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.537
Genes affected
LPL (HGNC:6677): (lipoprotein lipase) LPL encodes lipoprotein lipase, which is expressed in heart, muscle, and adipose tissue. LPL functions as a homodimer, and has the dual functions of triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake. Severe mutations that cause LPL deficiency result in type I hyperlipoproteinemia, while less extreme mutations in LPL are linked to many disorders of lipoprotein metabolism. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.51).
BP6
Variant 8-19951924-G-A is Benign according to our data. Variant chr8-19951924-G-A is described in ClinVar as [Benign]. Clinvar id is 362407.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr8-19951924-G-A is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=-0.537 with no splicing effect.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.109 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LPL | NM_000237.3 | c.405G>A | p.Val135Val | synonymous_variant | 3/10 | ENST00000650287.1 | NP_000228.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LPL | ENST00000650287.1 | c.405G>A | p.Val135Val | synonymous_variant | 3/10 | NM_000237.3 | ENSP00000497642.1 | |||
LPL | ENST00000520959.5 | c.177G>A | p.Val59Val | synonymous_variant | 3/5 | 4 | ENSP00000428496.1 | |||
LPL | ENST00000524029.5 | c.*16G>A | downstream_gene_variant | 4 | ENSP00000428237.1 |
Frequencies
GnomAD3 genomes AF: 0.0546 AC: 8298AN: 152076Hom.: 346 Cov.: 32
GnomAD3 genomes
AF:
AC:
8298
AN:
152076
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0332 AC: 8353AN: 251430Hom.: 225 AF XY: 0.0313 AC XY: 4247AN XY: 135890
GnomAD3 exomes
AF:
AC:
8353
AN:
251430
Hom.:
AF XY:
AC XY:
4247
AN XY:
135890
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0320 AC: 46818AN: 1461852Hom.: 998 Cov.: 31 AF XY: 0.0316 AC XY: 22997AN XY: 727228
GnomAD4 exome
AF:
AC:
46818
AN:
1461852
Hom.:
Cov.:
31
AF XY:
AC XY:
22997
AN XY:
727228
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0546 AC: 8317AN: 152194Hom.: 347 Cov.: 32 AF XY: 0.0535 AC XY: 3977AN XY: 74390
GnomAD4 genome
AF:
AC:
8317
AN:
152194
Hom.:
Cov.:
32
AF XY:
AC XY:
3977
AN XY:
74390
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
38
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:4
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 07, 2017 | Variant summary: The LPL c.405G>A (p.Val135Val) variant involves the alteration of a non-conserved nucleotide, resulting in a synonymous change. One in silico tool predicts a polymorphism outcome for this variant. 5/5 splice prediction tools predict no significant impact on normal splicing. ESE finder predicts that this variant may affect ESE site of SF2/ASF. This variant was found in 4195/121380 control chromosomes (117 homozygotes) from ExAC, predominantly observed in the African subpopulation at a frequency of 0.116997 (1217/10402). This frequency is about 35 times the estimated maximal expected allele frequency of a pathogenic LPL variant (0.0033541), thus this is a benign polymorphism found primarily in the populations of African origin. This variant was also not associated with Type 2 diabetes or lowered HDL-C levels in a case-control study from India (Ayyappa_2017). One clinical laboratory (via ClinVar) has classified this variant as likely benign. Taken together, this variant is classified as benign. - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Nov 19, 2018 | - - |
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Hyperlipoproteinemia, type I Benign:1
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
Dystrophin deficiency Benign:1
Benign, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Cardiovascular phenotype Benign:1
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 03, 2019 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at